• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
11
Dec
2015

Carter’s Immunotherapy Triumph, Wu-Tang Biopharma & A Gut-Brain Startup

/
Luke Timmerman
/
0
/
All
11 Dec 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Dec
2015

Family Offices: A Quiet, Emerging Force in Biotech Investing

/
Luke Timmerman
/
1
/
All, Drugs, People, The Edge, Venture Capital
07 Dec 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Dec
2015

PfizerGan Stirs the Pot, Boston Pharma’s $600M Bang & HepC Drug Pricing Back in the News

/
Luke Timmerman
/
0
/
All, Politics
04 Dec 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Nov
2015

Free Speech Should Be for R&D People Too, Not Just Sales & Marketing

/
Luke Timmerman
/
0
/
All, People
30 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Nov
2015

Commentary on the FDA Duchenne Panel With Meg Tirrell

/
Luke Timmerman
/
0
/
All, Drugs
25 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Nov
2015

Promise and Peril in the Scientific Enterprise: Q&A With MIT’s Bob Langer

/
Luke Timmerman
/
1
/
All, People, Politics, Science, The Edge
23 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Nov
2015

A16Z Digs Biotech, Clovis Crashes & FDA Smacks Down Supplements

/
Luke Timmerman
/
0
/
All, FDA
20 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Nov
2015

Google Knows What’s in Your Inbox, But It Shouldn’t Get Your Genome Without Consent

/
Kyle Serikawa
/
3
/
All, Genomics
19 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Nov
2015

Rewriting Pharma’s Broken Social Contract: Q&A with Alnylam’s John Maraganore

/
Luke Timmerman
/
8
/
All, Politics, The Edge
16 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Nov
2015

Pfizer Sizes Up Young Gun, CRISPR in the Spotlight & More Bad Behavior

/
Luke Timmerman
/
0
/
All
13 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Nov
2015

Pursuing a Hard Cancer Target: Q&A With Warp Drive CEO Laurence Reid

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
10 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Nov
2015

Raiding the Talent at Pfizer: Where Might The R&D Brains Go?

/
Luke Timmerman
/
3
/
All, Drugs, People, The Edge
09 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Nov
2015

D.C. Crosshairs on Pharma, ASH Roller Coaster & An IPO Cooldown

/
Luke Timmerman
/
0
/
All, Drugs, Politics
06 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Nov
2015

The $100M Club: See Who Makes the Cut in SF, Boston, and Beyond

/
Luke Timmerman
/
2
/
All, People, The Edge
02 Nov 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Oct
2015

Pfizer’s New MegaMerger Target, Valeant Burns & Amgen’s Cancer Advance

/
Luke Timmerman
/
0
/
All, Drugs
30 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Oct
2015

See the Photos From the TR1000 Party in SF

/
Luke Timmerman
/
1
/
All, People
27 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Oct
2015

Biotech Should Give More Young People a Chance

/
Luke Timmerman
/
14
/
All, People, The Edge
26 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Oct
2015

Investors Shouldn’t Nitpick Old Data. Bluebird’s New Gene Therapy Vector Makes a Difference

/
Zachary Fink
/
1
/
All, Drugs
23 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Oct
2015

Valeant’s Takedown, FDA Black Boxes & the Cancer Vaccine Scramble

/
Luke Timmerman
/
0
/
All
23 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Oct
2015

Playing Hardball: Academia Looks to Even the Score with VCs, Big Pharma

/
Luke Timmerman
/
1
/
All, The Edge
19 Oct 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 72 73 74 75 76 … 80 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder